Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer

Cell Reports

Volumn 16, Issue 7, 2016, Pages 2017-2031

  Witkiewicz, Agnieszka K ^a,b,c,d   Balaji, Uthra ^a   Eslinger, Cody ^a   McMillan, Elizabeth ^a   Conway, William ^e   Posner, Bruce ^f   Mills, Gordon B ^g   O'Reilly, Eileen M ^h   Knudsen, Erik S ^a,b,c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e Ochsner Medical Center   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ALPELISIB; ANTINEOPLASTIC AGENT; CHIR 125; DASATINIB; DOCETAXEL; EVEROLIMUS; GEMCITABINE; GSK 126; GSK 343; IMD 0354; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MUBRITINIB; PEMETREXED; PICTILISIB; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; EXOME; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CARCINOMA, PANCREATIC DUCTAL; DRUG SCREENING; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PROGNOSIS; STATISTICAL MODEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DASATINIB; DRUG RESISTANCE, NEOPLASM; EVEROLIMUS; EXOME; HUMANS; MICE; MODELS, GENETIC; MODELS, STATISTICAL; PANCREATIC NEOPLASMS; PRECISION MEDICINE; PROGNOSIS; PYRIDONES; PYRIMIDINONES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84997637203     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.07.023     Document Type: Article

References (35)

1. Almhanna, K., Philip, P.A., Defining new paradigms for the treatment of pancreatic cancer. Curr. Treat. Options Oncol. 12 (2011), 111–125.
2. Aparicio, S., Hidalgo, M., Kung, A.L., Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15 (2015), 311–316.
3. Aronson, S.J., Rehm, H.L., Building the foundation for genomics in precision medicine. Nature 526 (2015), 336–342.
4. Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., et al., Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52.
5. Balko, J.M., Cook, R.S., Vaught, D.B., Kuba, M.G., Miller, T.W., Bhola, N.E., Sanders, M.E., Granja-Ingram, N.M., Smith, J.J., Meszoely, I.M., et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18 (2012), 1052–1059.
6. Biankin, A.V., Piantadosi, S., Hollingsworth, S.J., Patient-centric trials for therapeutic development in precision oncology. Nature 526 (2015), 361–370.
7. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, I.-M., Conejo-Garcia, J.R., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238.
8. Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
9. Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483 (2012), 613–617.
10. Collisson, E.A., Sadanandam, A., Olson, P., Gibb, W.J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G.E., Jakkula, L., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17 (2011), 500–503.
11. Collisson, E.A., Trejo, C.L., Silva, J.M., Gu, S., Korkola, J.E., Heiser, L.M., Charles, R.P., Rabinovich, B.A., Hann, B., Dankort, D., et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2 (2012), 685–693.
12. Crystal, A.S., Shaw, A.T., Sequist, L.V., Friboulet, L., Niederst, M.J., Lockerman, E.L., Frias, R.L., Gainor, J.F., Amzallag, A., Greninger, P., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346 (2014), 1480–1486.
13. Deluche, E., Onesti, E., Andre, F., Precision medicine for metastatic breast cancer. Am. Soc. Clin. Oncol. Educ. Book 2015 (2015), e2–e7.
14. Evers, L., Perez-Mancera, P.A., Lenkiewicz, E., Tang, N., Aust, D., Knösel, T., Rümmele, P., Holley, T., Kassner, M., Aziz, M., et al. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med., 6, 2014, 9.
15. Garrido-Laguna, I., Tometich, D., Hu, N., Ying, J., Geiersbach, K., Whisenant, J., Wang, K., Ross, J.S., Sharma, S., N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience 2 (2015), 285–293.
16. Geserick, P., Wang, J., Feoktistova, M., Leverkus, M., The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin. Cell Death Dis., 5, 2014, e1412.
17. Infante, J.R., Somer, B.G., Park, J.O., Li, C.P., Scheulen, M.E., Kasubhai, S.M., Oh, D.Y., Liu, Y., Redhu, S., Steplewski, K., Le, N., A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. Cancer 50 (2014), 2072–2081.
18. Jänne, P.A., Mann, H., Ghiorghiu, D., Study design and rationale for a randomized, placebo-controlled, double-blind study to assess the efficacy and safety of selumetinib in combination with docetaxel as second-line treatment in patients with KRAS-mutant advanced non-small cell lung cancer (SELECT-1). Clin. Lung Cancer 17 (2016), e1–e4.
19. Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008), 1801–1806.
20. Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., Wang, W., Haswell, J.R., Walensky, L.D., Hahn, W.C., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21 (2015), 1491–1496.
21. Kleger, A., Perkhofer, L., Seufferlein, T., Smarter drugs emerging in pancreatic cancer therapy. Ann. Oncol. 25 (2014), 1260–1270.
22. Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., Jenkins, R.B., Kwiatkowski, D.J., Saldivar, J.S., Squire, J., et al., College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 15 (2013), 415–453.
23. Lowery, M.A., Kelsen, D.P., Stadler, Z.K., Yu, K.H., Janjigian, Y.Y., Ludwig, E., D'Adamo, D.R., Salo-Mullen, E., Robson, M.E., Allen, P.J., et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16 (2011), 1397–1402.
24. McDaid, H.M., Lopez-Barcons, L., Grossman, A., Lia, M., Keller, S., Pérez-Soler, R., Horwitz, S.B., Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 65 (2005), 2854–2860.
25. Mirzoeva, O.K., Das, D., Heiser, L.M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N.J., Neve, R.M., Guan, Y., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69 (2009), 565–572.
26. Paulson, A.S., Tran Cao, H.S., Tempero, M.A., Lowy, A.M., Therapeutic advances in pancreatic cancer. Gastroenterology 144 (2013), 1316–1326.
27. Pettazzoni, P., Viale, A., Shah, P., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 75 (2015), 1091–1101.
28. Saif, M.W., Advancements in the management of pancreatic cancer: 2013. JOP 14 (2013), 112–118.
29. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., Settleman, J., A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15 (2009), 489–500.
30. Solomon, D.A., Kim, T., Diaz-Martinez, L.A., Fair, J., Elkahloun, A.G., Harris, B.T., Toretsky, J.A., Rosenberg, S.A., Shukla, N., Ladanyi, M., et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333 (2011), 1039–1043.
31. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
32. Vora, S.R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E.L., Pollack, S.F., Liu, M., Li, X., et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26 (2014), 136–149.
33. Waddell, N., Pajic, M., Patch, A.M., Chang, D.K., Kassahn, K.S., Bailey, P., Johns, A.L., Miller, D., Nones, K., Quek, K., et al., Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518 (2015), 495–501.
34. Witkiewicz, A.K., McMillan, E.A., Balaji, U., Baek, G., Lin, W.C., Mansour, J., Mollaee, M., Wagner, K.U., Koduru, P., Yopp, A., et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun., 6, 2015, 6744.
35. Yeo, C.J., Cameron, J.L., Lillemoe, K.D., Sitzmann, J.V., Hruban, R.H., Goodman, S.N., Dooley, W.C., Coleman, J., Pitt, H.A., Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann. Surg. 221 (1995), 721–731 discussion 731–733.